Acrivon Therapeutics, Inc. (ACRV)
| Market Cap | 62.14M -13.4% |
| Revenue (ttm) | n/a |
| Net Income | -74.23M |
| EPS | -1.88 |
| Shares Out | 42.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 199,706 |
| Open | 1.470 |
| Previous Close | 1.460 |
| Day's Range | 1.400 - 1.500 |
| 52-Week Range | 1.270 - 3.560 |
| Beta | 1.98 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+693.1%) |
| Est. Earnings | Nov 27, 2026 |
About ACRV
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is AC... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ACRV stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 693.10% from the latest price.
News
Acrivon Therapeutics Transcript: KOL event
ACR-525 is positioned for EoE based on JAK1 selectivity, broad pathway effects, oral formulations, and encouraging early phase I findings. Management outlined potential phase II designs and combination opportunities, while efficacy, longer-term safety, and regulatory differentiation remain to be tested.
Acrivon Therapeutics Press release: KOL event
Acrivon Therapeutics issued a press release on November 10, 2026, disclosing material business information to investors.
Acrivon Therapeutics acquires ACR-525 program from Aqilion
Acrivon Therapeutics (ACRV) announced that it has acquired ACR-525, a Phase 2-ready, oral, highly selective Janus kinase 1, or JAK1, inhibitor, and a protein kinase C theta, or PKC, inhibitor…
Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB
Asset acquisition establishes immunology and inflammation (I&I) as a strategic pillar alongside oncology, extending the company into autoimmune disease
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing p...
Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
Timothy A. Yap, MBBS, Ph.D., FRCP, of The University of Texas MD Anderson Cancer Center to present results from the dose escalation phase of the ACR-2316 Phase 1/2 trial on November 20, 2026 Durable c...
Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent a...
Acrivon Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The AP3 platform enables rapid, AI-driven drug development by matching drug effects to disease pathways, validated in internal and in-licensed assets. Lead programs: phase II-B CHK1/2 inhibitor for serous endometrial cancer, dual WEE1/PKMYT1 inhibitor in phase II, and preclinical CDK11 inhibitor for AML. Interim ACR-368 data show promising efficacy and safety.
Acrivon Therapeutics Slides: Corporate presentation
Acrivon Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 7, 2026.
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing ...
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy Experienced biotechnology executive brings an ext...
Acrivon Therapeutics reports Q2 EPS (43c), consensus (50c)
“As we look ahead to the second half of 2026, we remain excited about the continued rapid clinical advancement of our precision medicine pipeline,” said Peter Blume-Jensen, chief executive officer,…
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026
Acrivon Therapeutics Quarterly report: Q2 2026
Acrivon Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Acrivon Therapeutics Earnings release: Q2 2026
Acrivon Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Acrivon Therapeutics Slides: Corporate presentation
Acrivon Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regime...
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic i...
Acrivon Therapeutics assumed with an Outperform at Oppenheimer
Oppenheimer analyst Jeff Jones assumed coverage of Acrivon Therapeutics (ACRV) with an Outperform rating and $8 price target ahead of important updates later this year from the ACR-368 program. An…
Acrivon Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
ACR-368 demonstrates high response rates in serous endometrial cancer, far surpassing standard care, with rapid trial enrollment and a pivotal interim analysis planned for Q4. The pipeline includes promising assets for lung cancer and AML, supported by a predictive AI-driven platform.
Acrivon Therapeutics Proxy statement: Proxy filing
Acrivon Therapeutics filed a proxy statement on May 22, 2026, providing details for shareholder voting and corporate governance matters.
Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit
WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing pr...
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing pr...
Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)
“2026 is an important catalyst year for Acrivon as we advance our two differentiated, AP3-guided clinical oncology programs towards key data read-outs,” said Peter Blume-Jensen, chief executive office...
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms i...